Lobbying Update: $440,000 of CME GROUP INC lobbying was just disclosed

$440,000 of CME GROUP INC lobbying was just disclosed, from Q2 of 2025, in a new Lobbying Disclosure Act filing.

This included lobbying on issues like:

"Issues related to regulation of clearinghouses, swap data repositories, swap execution facilities, and designated contract markets; Issues related to CFTC Funding; Issues related to Derivatives Clearing Market Structure; Issues related to CFTC Reauthorization; Issues related to H.R. 3633 - Digital Asset Market Clarity Act of 2025 (Sec. 101; Definitions under the Securities Act of 1933, Sec. 102; Definitions under the Commodity Exchange Act, Sec. 103; Definitions under this Act, Sec. 107; Commodity Exchange Act savings provisions, Section 401; Commission jurisdiction over digital commodity transactions, and Section 409; Exclusion for Decentralized Finance Activities); Issues related to the Clearing of US Treasury futures. Issues related to H.R. 3633 - Digital Asset Market Clarity Act of 2025 (Sec. 101; Definitions under the Securities Act of 1933, Sec. 102; Definitions under the Commodity Exchange Act, Sec. 103; Definitions under this Act, Sec. 107; Commodity Exchange Act savings provisions, Section 401; Commission jurisdiction over digital commodity transactions, and Section 409; Exclusion for Decentralized Finance Activities); S. 394 - GENIUS Act of 2025 (all issues); H.R. 2392 - STABLE Act of 2025 (all issues); Issues related to Basel III Bank Capital Standards; Issues related to the Clearing of US Treasury futures. Issues related to tax treatment of futures, securities, and commodities; Issues related to Sec. 1256 of the tax code related to the tax treatment of futures and options."

You can find more data on corporate lobbying on Quiver Quantitative.

CME Congressional Stock Trading

Members of Congress have traded $CME stock 3 times in the past 6 months. Of those trades, 2 have been purchases and 1 have been sales.

Here’s a breakdown of recent trading of $CME stock by members of Congress over the last 6 months:

REPRESENTATIVE JEFFERSON SHREVE sold up to $50,000 on 05/12.
REPRESENTATIVE ROBERT BRESNAHAN purchased up to $15,000 on 04/08.
REPRESENTATIVE CAROL D. MILLER purchased up to $15,000 on 03/10.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.

CME Insider Trading Activity

CME insiders have traded $CME stock on the open market 26 times in the past 6 months. Of those trades, 6 have been purchases and 20 have been sales.

Here’s a breakdown of recent trading of $CME stock by insiders over the last 6 months:

TERRENCE A DUFFY (Chairman and CEO) sold 30,000 shares for an estimated $7,775,400
JULIE WINKLER (Sr MD Chief Commercial Officer) sold 11,592 shares for an estimated $2,888,378
HOWARD J SIEGEL sold 10,000 shares for an estimated $2,600,000
DEREK SAMMANN (Sr MD Gl Hd Commodities Mkts) has made 0 purchases and 2 sales selling 4,650 shares for an estimated $1,304,847.
KEN VROMAN (Chief Transformation Officer) sold 5,066 shares for an estimated $1,266,500
LARRY G GERDES has made 0 purchases and 3 sales selling 4,000 shares for an estimated $1,060,441.
HILDA HARRIS PIELL (Sr MD & Chief HR Officer) sold 3,984 shares for an estimated $997,852
CHARLES P CAREY has made 0 purchases and 3 sales selling 3,500 shares for an estimated $950,356.
WILLIAM R SHEPARD has made 6 purchases buying 1,970 shares for an estimated $470,129 and 0 sales.
DEBORAH J LUCAS sold 1,500 shares for an estimated $385,425
SUZANNE SPRAGUE (COO & Global Head of Clearing) sold 1,500 shares for an estimated $385,249
PHYLLIS M LOCKETT sold 1,060 shares for an estimated $294,552
DENNIS SUSKIND sold 1,000 shares for an estimated $271,280
DANIEL G KAYE sold 500 shares for an estimated $141,209
JONATHAN L MARCUS (Sr MD General Counsel) sold 390 shares for an estimated $108,225
MARTIN J GEPSMAN sold 300 shares for an estimated $81,951

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

CME Hedge Fund Activity

We have seen 767 institutional investors add shares of CME stock to their portfolio, and 642 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

BLACKROCK, INC. added 2,987,980 shares (+10.1%) to their portfolio in Q1 2025, for an estimated $792,681,214
PRICE T ROWE ASSOCIATES INC /MD/ removed 2,832,475 shares (-34.2%) from their portfolio in Q1 2025, for an estimated $751,427,292
GQG PARTNERS LLC added 2,176,685 shares (+7676.3%) to their portfolio in Q1 2025, for an estimated $577,452,763
WELLINGTON MANAGEMENT GROUP LLP added 2,089,935 shares (+370.5%) to their portfolio in Q1 2025, for an estimated $554,438,856
GAMMA INVESTING LLC removed 1,850,590 shares (-99.6%) from their portfolio in Q2 2025, for an estimated $510,059,615
JPMORGAN CHASE & CO added 1,780,700 shares (+16.5%) to their portfolio in Q1 2025, for an estimated $472,401,903
CAPITAL INTERNATIONAL INVESTORS added 1,745,458 shares (+64.9%) to their portfolio in Q1 2025, for an estimated $463,052,552

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

CME Analyst Ratings

Wall Street analysts have issued reports on $CME in the last several months. We have seen 5 firms issue buy ratings on the stock, and 2 firms issue sell ratings.

Here are some recent analyst ratings:

Piper Sandler issued a "Overweight" rating on 07/15/2025
Oppenheimer issued a "Outperform" rating on 06/04/2025
UBS issued a "Buy" rating on 04/25/2025
Morgan Stanley issued a "Overweight" rating on 04/24/2025
JP Morgan issued a "Underweight" rating on 04/24/2025
B of A Securities issued a "Underperform" rating on 04/02/2025
Raymond James issued a "Outperform" rating on 03/10/2025

To track analyst ratings and price targets for CME, check out Quiver Quantitative's $CME forecast page.

CME Price Targets

Multiple analysts have issued price targets for $CME recently. We have seen 12 analysts offer price targets for $CME in the last 6 months, with a median target of $291.5.

Here are some recent targets:

Patrick Moley from Piper Sandler set a target price of $296.0 on 07/15/2025
Benjamin Budish from Barclays set a target price of $299.0 on 07/10/2025
Christopher Allen from Citigroup set a target price of $275.0 on 07/03/2025
Owen Lau from Oppenheimer set a target price of $300.0 on 06/04/2025
Alex Kramm from UBS set a target price of $305.0 on 04/25/2025
Kenneth Worthington from JP Morgan set a target price of $211.0 on 04/24/2025
Kyle Voigt from Keefe, Bruyette & Woods set a target price of $273.0 on 04/24/2025

This article is not financial advice. See Quiver Quantitative's disclaimers for more information.